Ganciclovir Treatment of Cytomegalovirus Disease in Transplant Recipients and Other Immunocompromised Hosts

Alejo Erice, M. Colin Jordan, Beverly A. Chace, Courtney Fletcher, Barbara J. Chinnock, Henry H. Balfour

Research output: Contribution to journalArticle

200 Citations (Scopus)

Abstract

Thirty-one immunocompromised patients with severe cytomegalovirus (CMV) disease were treated with intravenous ganciclovir. Twenty-one patients had received transplants—15 bone marrow recipients, five renal allograft recipients, and one liver transplant recipient—while the other ten were immunocompromised due to acquired immunodeficiency syndrome (six), hematologic malignancies (three), and systemic lupus erythematosus (one). They presented with one or more of the following syndromes: CMV pneumonitis (19), CMV of the gastrointestinal tract (six), CMV retinitis (seven), and CMV hepatitis (three). Seventeen (55%) of 31 patients demonstrated clinical improvement during ganciclovir therapy, with the best response seen in the transplant recipients. Viremia ceased in 14 (93.3%) of 15 patients after a mean of 4.7 days of therapy; viruria ceased in eight (53.3%) of 15 patients after a mean of 11 days of therapy. Ganciclovir plasma concentrations at a dosage of 2.5 mg/kg/three times a day were as follows: mean peak, 16.04 μmol/L; mean trough, 2.38 μmol/L. Neutropenia occurred in 11 (35%) of 31 patients and in nine (60%) of 15 bone marrow transplant recipients. We conclude that ganciclovir exerted an antiviral effect against CMV and may play a role in the treatment of CMV disease in patients with depressed immunity, especially bone marrow and organ transplant recipients.

Original languageEnglish (US)
Pages (from-to)3082-3087
Number of pages6
JournalJAMA: The Journal of the American Medical Association
Volume257
Issue number22
DOIs
StatePublished - Jun 12 1987

Fingerprint

Ganciclovir
Immunocompromised Host
Cytomegalovirus
Bone Marrow
Therapeutics
Cytomegalovirus Retinitis
Transplants
Viremia
Hematologic Neoplasms
Neutropenia
Systemic Lupus Erythematosus
Hepatitis
Antiviral Agents
Allografts
Gastrointestinal Tract
Transplant Recipients
Immunity
Pneumonia
Acquired Immunodeficiency Syndrome
Kidney

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Ganciclovir Treatment of Cytomegalovirus Disease in Transplant Recipients and Other Immunocompromised Hosts. / Erice, Alejo; Jordan, M. Colin; Chace, Beverly A.; Fletcher, Courtney; Chinnock, Barbara J.; Balfour, Henry H.

In: JAMA: The Journal of the American Medical Association, Vol. 257, No. 22, 12.06.1987, p. 3082-3087.

Research output: Contribution to journalArticle

Erice, Alejo ; Jordan, M. Colin ; Chace, Beverly A. ; Fletcher, Courtney ; Chinnock, Barbara J. ; Balfour, Henry H. / Ganciclovir Treatment of Cytomegalovirus Disease in Transplant Recipients and Other Immunocompromised Hosts. In: JAMA: The Journal of the American Medical Association. 1987 ; Vol. 257, No. 22. pp. 3082-3087.
@article{065ca2759c50489fada0680d4fe73bbb,
title = "Ganciclovir Treatment of Cytomegalovirus Disease in Transplant Recipients and Other Immunocompromised Hosts",
abstract = "Thirty-one immunocompromised patients with severe cytomegalovirus (CMV) disease were treated with intravenous ganciclovir. Twenty-one patients had received transplants—15 bone marrow recipients, five renal allograft recipients, and one liver transplant recipient—while the other ten were immunocompromised due to acquired immunodeficiency syndrome (six), hematologic malignancies (three), and systemic lupus erythematosus (one). They presented with one or more of the following syndromes: CMV pneumonitis (19), CMV of the gastrointestinal tract (six), CMV retinitis (seven), and CMV hepatitis (three). Seventeen (55{\%}) of 31 patients demonstrated clinical improvement during ganciclovir therapy, with the best response seen in the transplant recipients. Viremia ceased in 14 (93.3{\%}) of 15 patients after a mean of 4.7 days of therapy; viruria ceased in eight (53.3{\%}) of 15 patients after a mean of 11 days of therapy. Ganciclovir plasma concentrations at a dosage of 2.5 mg/kg/three times a day were as follows: mean peak, 16.04 μmol/L; mean trough, 2.38 μmol/L. Neutropenia occurred in 11 (35{\%}) of 31 patients and in nine (60{\%}) of 15 bone marrow transplant recipients. We conclude that ganciclovir exerted an antiviral effect against CMV and may play a role in the treatment of CMV disease in patients with depressed immunity, especially bone marrow and organ transplant recipients.",
author = "Alejo Erice and Jordan, {M. Colin} and Chace, {Beverly A.} and Courtney Fletcher and Chinnock, {Barbara J.} and Balfour, {Henry H.}",
year = "1987",
month = "6",
day = "12",
doi = "10.1001/jama.1987.03390220080025",
language = "English (US)",
volume = "257",
pages = "3082--3087",
journal = "JAMA - Journal of the American Medical Association",
issn = "0002-9955",
publisher = "American Medical Association",
number = "22",

}

TY - JOUR

T1 - Ganciclovir Treatment of Cytomegalovirus Disease in Transplant Recipients and Other Immunocompromised Hosts

AU - Erice, Alejo

AU - Jordan, M. Colin

AU - Chace, Beverly A.

AU - Fletcher, Courtney

AU - Chinnock, Barbara J.

AU - Balfour, Henry H.

PY - 1987/6/12

Y1 - 1987/6/12

N2 - Thirty-one immunocompromised patients with severe cytomegalovirus (CMV) disease were treated with intravenous ganciclovir. Twenty-one patients had received transplants—15 bone marrow recipients, five renal allograft recipients, and one liver transplant recipient—while the other ten were immunocompromised due to acquired immunodeficiency syndrome (six), hematologic malignancies (three), and systemic lupus erythematosus (one). They presented with one or more of the following syndromes: CMV pneumonitis (19), CMV of the gastrointestinal tract (six), CMV retinitis (seven), and CMV hepatitis (three). Seventeen (55%) of 31 patients demonstrated clinical improvement during ganciclovir therapy, with the best response seen in the transplant recipients. Viremia ceased in 14 (93.3%) of 15 patients after a mean of 4.7 days of therapy; viruria ceased in eight (53.3%) of 15 patients after a mean of 11 days of therapy. Ganciclovir plasma concentrations at a dosage of 2.5 mg/kg/three times a day were as follows: mean peak, 16.04 μmol/L; mean trough, 2.38 μmol/L. Neutropenia occurred in 11 (35%) of 31 patients and in nine (60%) of 15 bone marrow transplant recipients. We conclude that ganciclovir exerted an antiviral effect against CMV and may play a role in the treatment of CMV disease in patients with depressed immunity, especially bone marrow and organ transplant recipients.

AB - Thirty-one immunocompromised patients with severe cytomegalovirus (CMV) disease were treated with intravenous ganciclovir. Twenty-one patients had received transplants—15 bone marrow recipients, five renal allograft recipients, and one liver transplant recipient—while the other ten were immunocompromised due to acquired immunodeficiency syndrome (six), hematologic malignancies (three), and systemic lupus erythematosus (one). They presented with one or more of the following syndromes: CMV pneumonitis (19), CMV of the gastrointestinal tract (six), CMV retinitis (seven), and CMV hepatitis (three). Seventeen (55%) of 31 patients demonstrated clinical improvement during ganciclovir therapy, with the best response seen in the transplant recipients. Viremia ceased in 14 (93.3%) of 15 patients after a mean of 4.7 days of therapy; viruria ceased in eight (53.3%) of 15 patients after a mean of 11 days of therapy. Ganciclovir plasma concentrations at a dosage of 2.5 mg/kg/three times a day were as follows: mean peak, 16.04 μmol/L; mean trough, 2.38 μmol/L. Neutropenia occurred in 11 (35%) of 31 patients and in nine (60%) of 15 bone marrow transplant recipients. We conclude that ganciclovir exerted an antiviral effect against CMV and may play a role in the treatment of CMV disease in patients with depressed immunity, especially bone marrow and organ transplant recipients.

UR - http://www.scopus.com/inward/record.url?scp=84944367245&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84944367245&partnerID=8YFLogxK

U2 - 10.1001/jama.1987.03390220080025

DO - 10.1001/jama.1987.03390220080025

M3 - Article

C2 - 3035246

AN - SCOPUS:84944367245

VL - 257

SP - 3082

EP - 3087

JO - JAMA - Journal of the American Medical Association

JF - JAMA - Journal of the American Medical Association

SN - 0002-9955

IS - 22

ER -